Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to provide allogeneic stem cell transplantation to patients who
have not traditionally undergone this procedure because of it high incidence of treatment
related side effects. We hope to decrease these side effects by decreasing the chemotherapy
dose prior to transplant (non-myeloablative, smaller dose of chemotherapy given so bone
marrow is not completely eliminated) and by using donated stem cells to treat cancer of the
blood.